Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models

Area of Science:

• Oncology
• Medical Imaging
• Translational Medicine

Background:

• Precision medicine aims to enhance diagnostic accuracy and reduce treatment failures.
• Biomarker discovery and early detection of therapeutic response are crucial for breast cancer management.
• Animal models are vital for evaluating novel imaging and therapeutic strategies before human trials.

Purpose of the Study:

• To review recent advancements in preclinical molecular imaging for breast cancer mouse models.
• To highlight the role of imaging biomarkers in patient stratification and treatment monitoring.

Main Methods:

• Review of preclinical studies utilizing molecular imaging techniques in breast cancer models.
• Focus on Positron Emission Tomography (PET) for in vivo biomarker evaluation.
• Emphasis on Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) for assessing treatment response.

Main Results:

• PET imaging is a common method for assessing biomarker expression in vivo.
• DW-MRI can noninvasively distinguish between responders and nonresponders to various therapies with high sensitivity.
• Molecular imaging in animal models facilitates understanding of disease mechanisms.

Conclusions:

• Preclinical molecular imaging, particularly PET and DW-MRI, is essential for advancing precision medicine in breast cancer.
• These techniques aid in biomarker discovery, patient stratification, and early prediction of therapeutic efficacy.
• Continued use of animal models is critical for developing tailored breast cancer treatments.